Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 13Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 6Lymphoma, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Immune System Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Proteostasis Deficiencies 1

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × Bendamustine Hydrochloride × Clear all
NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Completed
27 enrolled 12 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡